ADIM
IBB icon

Alpha DNA Investment Management’s iShares Biotechnology ETF IBB Stock Holding History

Alpha DNA Investment Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-216
Closed -$32K – 342
2021
Q1 		$32K Hold
216
– – 0.04% 219
2020
Q4 		$32K Buy
+216
New +$30.9K 0.03% 219

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Alpha DNA Investment Management's IBB Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of iShares Biotechnology ETF (IBB) in Q2 2021, closing a stake of 216 shares — an estimated $32K sold.

Alpha DNA Investment Management first reported a position in IBB in Q4 2020 and held it in 2 quarters. The position peaked at $32K in Q1 2021. 864 funds tracked by Wall St. Rank hold IBB as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining iShares Biotechnology ETF position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 216 iShares Biotechnology ETF shares in Q2 2021, an estimated $32K.
  • Alpha DNA Investment Management first reported a position in iShares Biotechnology ETF in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's iShares Biotechnology ETF position peaked at $32K in Q1 2021.
  • 864 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.